CEO Spills Exon-Skipper News: Sarepta DMD Filing Next Year
In Wall Street's view, the outcome of another meeting between the FDA and Sarepta Therapeutics Inc. apparently did not bring enough about the path to a new drug application (NDA) filing for eteplirsen, the exon-skipping therapy for Duchenne muscular dystrophy (DMD).
Suite: 1100 | Atlanta, Georgia 30346, USA
Outside of the US
In the U.S. and Canada: +1-800-336-4474
Outside the U.S.: +44-203-684-1796
Hours: Monday - Friday, 8:00am - 6:00 pm EST
Sign up for Highlights FREE e-mail newsletter